Amos is a Special Partner at Apax Partners managing the existing Apax healthcare venture portfolio and a private active investor. Amos joined Apax in 1997 and until 2007 was an Equity Partner and the Head of Apax Healthcare Europe and co-Head of Apax’s global healthcare practice. Amos led the Apax investments in Dune as Chairman since 2004. Amos directed many of Apax’s investments in medtech and biotechnology in Europe, the US and Israel including Aerovance, Astex, Cadent, Compugen. Prior to Apax, Amos was an executive involved in turnarounds of manufacturing companies in Israel and CEO of a speciality pharma company in the US which he founded and sold. Amos received his MBA from Harvard Business School, MSc from the Weizmann Institute and BSc from the Hebrew University.
Lori is a seasoned veteran in the healthcare space beginning her career as a CCRN working in critical care, trauma and emergency medicine at Yale New Haven Hospital, Emory University Hospital and St Joseph’s of Atlanta. She transitioned into the medical device industry as a Clinical Specialist with Datascope, now Maquet and with a track record of success took on increasing levels of leadership completing her 10 year tenure as the Vice President of North American Sales. She spent time as a regional Corporate Sales Director for Medtronic and then moved over to Covidien Endo mechanical where she spent 4 years as the VP of Sales and Marketing. Most recently she served as the VP of the US for Cordis, a Johnson and Johnson company. Lori is known as a champion of change management and passionate about delivering growth. She has led numerous Women’s leadership imperatives and currently serves as the President on the Atlanta Chapter board for the Healthcare Business women’s Association in addition to being on the board of directors for the Pine Crest Academy in Atlanta. Lori earned a BSN from Southern Connecticut State University.
Dr. Paul Enever
Paul is an adviser with Canepa U.S., where he oversees the Canepa Advanced Healthcare Fund’s strategy and investments of its Advanced Healthcare portfolio. He serves on the Boards of Directors of Cardiva Medical, Dune Medical, and Knome. Before joining Canepa, Paul was a partner with McKinsey and Company. Previously, Paul worked within the R&D organization at Sandoz Pharmaceuticals and MIT’s Biotechnology Process Engineering Center. He has a B.S. in chemical engineering from Rensselaer Polytechnic Institute and a Ph.D. in chemical engineering from the University of Minnesota where he studied wound healing and tissue engineering. For his work, Paul was the recipient of both a National Science Foundation Graduate Fellowship and the Whitaker Foundation Graduate Fellowship in Biomedical Engineering.
Daniel J. Levangie
Daniel Levangie, an experienced executive with senior operating experience in the field of medical devices and in vitro diagnostics, is co-founder and Managing Partner of newly formed ATON Partners, a private investment and management consulting firm. Most recently Mr. Levangie was Chief Executive Officer of Dune Medical Devices and co-founder and Managing Partner of Constitution Medical Investors, Inc. (CMI) a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation in July 2013.
Prior to the above, Mr. Levangie held a variety of executive management positions with Cytyc Corporation until the acquisition of Cytyc Corporation by Hologic, Inc. in October of 2007. Mr. Levangie held a variety of senior management positions with Cytyc Corporation including Executive Vice President and Chief Operating Officer, Chief Executive Officer and President of Cytyc Health Corporation, Executive Vice President and Chief Commercial Officer and President, Cytyc Surgical Products Division from July 2006 until October, 2007.
Prior to joining Cytyc Corporation in 1992, Mr. Levangie held a number of sales, marketing and management positions with Abbott Laboratories, North Chicago, IL.
Mr. Levangie resides in Boston, MA with his wife Joan, and is a member of the Board of Directors of Exact Sciences, Inc., Liposcience, Inc., Insulet Corporation, and Dune Medical Devices. Mr. Levangie, a graduate of Northeastern University in Boston, is a member of the Advisory Board of the Barnett Institute of Northeastern University and is a trustee of Excel Charter School.
Bill is Director of Investments for the Kraft Group LLC. Since joining the Kraft Group in 1992, he has been involved with a number of investing and operating initiatives, including the creation of a dedicated family investment office which he leads today. Bill serves as Board Member or Observer at C4 Therapeutics, Dune Medical Devices, Spero Therapeutics and Silk Therapeutics. Bill received a BSBA from Northeastern University and a MSIM from Boston University.